Imai Kengo, Morita Tatsuya, Yokomichi Naosuke, Mori Masanori, Naito Akemi Shirado, Yamauchi Toshihiro, Tsukuura Hiroaki, Uneno Yu, Tsuneto Satoru, Inoue Satoshi
Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Palliat Med Rep. 2022 Apr 8;3(1):47-54. doi: 10.1089/pmr.2021.0087. eCollection 2022.
Palliative sedation is sometimes needed for refractory symptoms, and the Richmond Agitation-Sedation Scale (RASS) is one of the key measures. The primary aim of this study was to explore the association between RASS and degree of distress quantified by other measures: Item "symptom control" of Support Team Assessment Schedule (STAS, item 2), Discomfort Scale for Dementia of Alzheimer Type (Discomfort Scale), and Noncommunicative Patient's Pain Assessment Instrument (NOPPAIN), as well as a communication capacity measured by the Communication Capacity Scale (CCS), item 4.
This was a prospective observational study on terminally ill cancer patients with palliative sedation in a palliative care unit of a designated cancer hospital. Primarily responsible palliative care physicians rated RASS, Discomfort Scale, NOPPAIN, and CCS just before sedation and 1, 4, 24, and 48 hours after, and ward nurses rated STAS at the same time. Since the ward nurses evaluated STAS during palliative sedation, we regarded STAS as a standard of distress measure.
A total of 249 assessments were performed for 55 patients. RASS was moderately to highly associated with symptom intensity measured by STAS, discomfort measured by the Discomfort Scale, and pain measured by NOPPAIN ( = 0.63 to 0.73). But communication capacity measured by CCS is not parallel with RASS and demonstrated a valley shape. In 82 assessments with an RASS score of -1 to -3, 11 patients (13%) had physical symptoms of STAS of 2 or more.
RASS can roughly estimate physical distress in patients with palliative sedation, but a measure to more precisely quantify the symptom experience is needed.
对于难治性症状有时需要进行姑息性镇静,而里士满躁动 - 镇静量表(RASS)是关键测量指标之一。本研究的主要目的是探讨RASS与通过其他测量方法量化的痛苦程度之间的关联:支持团队评估量表(STAS,项目2)的“症状控制”项目、阿尔茨海默病型痴呆不适量表(不适量表)、非言语患者疼痛评估工具(NOPPAIN),以及通过沟通能力量表(CCS,项目4)测量的沟通能力。
这是一项对指定癌症医院姑息治疗病房中接受姑息性镇静的晚期癌症患者进行的前瞻性观察研究。主要负责的姑息治疗医生在镇静前以及镇静后1、4、24和48小时对RASS、不适量表、NOPPAIN和CCS进行评分,病房护士同时对STAS进行评分。由于病房护士在姑息性镇静期间评估STAS,我们将STAS视为痛苦测量的标准。
对55名患者共进行了249次评估。RASS与通过STAS测量的症状强度、通过不适量表测量的不适以及通过NOPPAIN测量的疼痛中度至高度相关(= 0.63至0.73)。但通过CCS测量的沟通能力与RASS不平行,呈谷形。在82次RASS评分为 -1至 -3的评估中,11名患者(13%)的STAS身体症状为2或更高。
RASS可以大致估计接受姑息性镇静患者的身体痛苦,但需要一种更精确量化症状体验的测量方法。